- Approval Id
- d912d49a49d04cab
- Drug Approval Emc Name
- Vinorelbine 30mg Soft Capsules
- Drug Name
- Vinorelbine 30mg Soft Capsules
- Company Name
- medac Pharma LLP
- Company Address
- Scion House, Stirling University Innovation Park, Stirling, FK9 4NF, UK
- Company Website
- //www.medacpharma.co.uk
- Company Telephone
- +44 (0)1786 458 086
- Company Medical Info Email
- info@medacpharma.co.uk
- Atc Code
- L01CA04
- Legal Category
- Prescription only medicine
- Authorisation Holder
- medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstr. 6
22880 Wedel
Germany
- Authorisation Number
- PL 11587/0134
- Authorisation Date
- 24/04/2023
- Instruction Authorisation Holder
- medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstr. 6
22880 Wedel
Germany
- Instruction Authorisation Number
- PL 11587/0134
- Instruction Authorisation Date
- 24/04/2023
- Instruction Composition
- Each soft capsule contains vinorelbine tartrate equivalent to 30 mg vinorelbine
\*\*Excipient(s) with known effect\*\*
Each soft capsule containing 30 mg vinorelbine contains 15.96 mg sorbitol.
Each soft capsule containing 30 mg vinorelbine contains 7.5 mg ethanol.
For the full list of excipients, see section 6.1
- Instruction Dosage Form
- Soft capsules
An oblong-shaped pink soft with a size of 15.0 mm x 6.0mm capsule with black “30” printed on the surface.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
As a single agent or in combination for:
• The first line treatment of stage 3 or 4 non small cell lung cancer.
• The treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.4.2 Posology and method of administration
\*\*In adult patients\*\*
\*\*\*\*As a single agent,\*\*\*\* \*\*the recommended regimen is:\*\*
\*First three administrations\*
60 mg/m2 of body surface area, \*\*administered once weekly.\*\*
\*Subsequent administrations\*
Beyond the third administration, it is recommended to increase the dose of Vinorelbine medac to 80 mg/m2 once weekly except in those patients for whom the neutrophil count dropped once below 500/mm3 or more than once between 500 and 1000/mm3 during the first three administrations at 60 mg/m2.
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Neutrophil count during the first 3 administrations of 60 mg/m2/week\*\* | \*\*Neutrophils\*\* \*\*> 1000\*\* | \*\*Neutrophils\*\* \*\*≥ 500 and < 1000\*\* \*\*(1 episode)\*\* | \*\*Neutrophils\*\* \*\*≥ 500 and < 1000\*\* \*\*(2 episodes)\*\* | \*\*Neutrophils\*\* \*\*< 500\*\* |
| \*\*Recommended dose starting with the 4th administration\*\* | \*\*80\*\* | \*\*80\*\* | \*\*60\*\* | \*\*60\*\* |
\*Dose modification\*
For any administration planned to be given at 80 mg/m2, if the neutrophil count is below 500/mm3 or more than once between 500 and 1000/mm3, the administration should be delayed until recovery and the dose reduced from 80 to 60 mg/m2 per week during the 3 following administrations.
If the neutrophil count is below 1500/mm3 and/or the platelet count below 100000/mm3, then the treatment should be delayed until recovery.
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Neutrophil count beyond the 4th administration of 80 mg/m2/week\*\* | \*\*Neutrophils\*\* \*\*> 1000\*\* | \*\*Neutrophils\*\* \*\*≥ 500 and < 1000\*\* \*\*(1 episode)\*\* | \*\*Neutrophils\*\* \*\*≥ 500 and < 1000\*\* \*\*(2 episodes)\*\* | \*\*Neutrophils\*\* \*\*< 500\*\* |
| \*\*Recommended dose starting with the next administration\*\* | \*\*80\*\* | | \*\*60\*\* | |
It is possible to re-escalate the dose from 60 to 80 mg/m2 per week if the neutrophil count did not drop below 500/mm3 or more than once between 500 and 1000/mm3 during 3 administrations given at 60 mg/m2 according to the rules previously defined for the first 3 administrations.
\*\*For combination regimens, the dose and schedule will be adapted to the treatment protocol.\*\*
Based on clinical studies, the oral dose of 80 mg/m2 was demonstrated to correspond to 30 mg/m2 of the iv form and 60 mg/m2 to 25 mg/m2.
This has been the base for combination regimens alternating iv and oral forms to improve patients' convenience.
Capsules of different strengths (20, 30, 80 mg) are available in order to choose the adequate combination for the right dosage.
The following table gives the dose required for appropriate ranges of body surface area (BSA).
| | | |
| --- | --- | --- |
| | 60 mg/m2 | 80 mg/m2 |
| BSA (m2) | Dose (mg) | Dose (mg) |
| 0.95 to 1.04 | 60 | 80 |
| 1.05 to 1.14 | 70 | 90 |
| 1.15 to 1.24 | 70 | 100 |
| 1.25 to 1.34 | 80 | 100 |
| 1.35 to 1.44 | 80 | 110 |
| 1.45 to 1.54 | 90 | 120 |
| 1.55 to 1.64 | 100 | 130 |
| 1.65 to 1.74 | 100 | 140 |
| 1.75 to 1.84 | 110 | 140 |
| 1.85 to 1.94 | 110 | 150 |
| ≥ 1.95 | 120 | 160 |
Even for patients with BSA ≥ 2 m2 the total dose should never exceed 120 mg per week at 60 mg/m2 and 160 mg per week at 80 mg/m2.
\*\*Administration\*\*
Vinorelbine medac must be given strictly by the oral route.
The Vinorelbine medac capsules must be swallowed whole with water without chewing, sucking or dissolving the capsule.
It is recommended to administer the capsule with some food.
Specific instructions must be followed for the administration of vinorelbine (see section 6.6).
\*Administration in the elderly\*
Clinical experience has not detected any significant differences among elderly patients with regard to the response rate, although greater sensitivity in some of these patients cannot be excluded. Age does not modify the pharmacokinetics of vinorelbine (see section 5.2).
\*Administration in children\*
Safety and efficacy in children have not been established and administration is therefore not recommended.
\*Administration in patients with liver insufficiency\*
Vinorelbine can be administered at the standard dose of 60 mg/m2/week in patients with mild liver impairment (bilirubin < 1.5 x ULN, and ALAT and/or ASAT from 1.5 to 2.5 x ULN).
In patients with moderate liver impairment (bilirubin from 1.5 to 3 x ULN, whatever the levels of ALAT and ASAT), Vinorelbine medac should be administered at a dose of 50 mg/m2/week. The administration of vinorelbine to patients with severe hepatic impairment is contraindicated (see sections 4.3, 4.4 and 5.2).
\*Administration in patients with renal insufficiency\*
Given the minor renal excretion, there is no pharmacokinetic justification for reducing the dose of Vinorelbine medac in patients with serious renal insufficiency (see sections 4.4 and 5.2).4.3 Contraindications
- Known hypersensitivity to vinorelbine or other vinca alkaloids or to any of the constituents
- Disease significantly affecting absorption
- Previous significant surgical resection of stomach or small bowel
- Neutrophil count < 1500/mm3 or severe infection current or recent (within 2 weeks)
- Platelet count < 100 000/mm3
- Severe hepatic insufficiency
- Pregnancy (see section 4.6)
- Lactation (see section 4.6)
- Patients requiring long-term oxygen therapy
- In combination with yellow fever vaccine (see section 4.5)4.4 Special warnings and precautions for use
\*\*Special warnings\*\*
Vinorelbine medac should be prescribed by a physician who is experienced in the use of chemotherapy with facilities for monitoring cytotoxic drugs.
If the patient chews or sucks the capsule by error, the liquid is an irritant. Proceed to mouth rinses with water or preferably a normal saline solution.
In the event of the capsule being cut or damaged, the liquid content is an irritant, and so may cause damage if in contact with skin, mucosa or eyes. Damaged capsules should not be swallowed and should be returned to the pharmacy or to the doctor in order to be properly destroyed. If any contact occurs, immediate thorough washing with water or preferably with normal saline solution should be undertaken.
In the case of vomiting within a few hours after drug intake, do not re-administer. Supportive treatment such as metoclopramide or 5HT3 antagonists (e.g. ondansetron, granisetron) may reduce the occurrence of this (see section 4.5).
Vinorelbine medac is associated with a higher incidence of nausea/vomiting than the intravenous formulation. Primary prophylaxis with antiemetics and administration of the capsules with some food is recommended as this has also been shown to reduce the incidence of nausea and vomiting (see section 4.2).
Patients receiving concomitant morphine or opioid analgesics: laxatives and careful monitoring of bowel mobility are recommended. Prescription of laxatives may be appropriate in patients with prior history of constipation.
Close haematological monitoring must be undertaken during treatment (determination of haemoglobin level and the leucocyte, neutrophil and platelet counts on the day of each new administration).
Dosing should be determined by haematological status:
- If the neutrophil count is below 1500/mm3 and/or the platelet count is below 100 000/mm3, then the treatment should be delayed until recovery.
- For dose escalation from 60 to 80 mg/m2 per week after the third administration, please see section 4.2.
- For the administrations given at 80 mg/m2, if the neutrophil count is below 500/mm3 or more than once between 500 and 1000/mm3, then the treatment should be delayed until recovery. The administration should not only be delayed but also reduced to 60 mg/m2 per week. It is possible to re-escalate the dose from 60 to 80 mg/m2 per week, please see section 4.2.
During clinical trials where treatments were initiated at 80 mg/m2, a few patients developed excessive neutropenic complications, including those with a poor performance status. Therefore, it is recommended that the starting dose should be 60 mg/m2 escalating to 80 mg/m2 if the dose is tolerated as described in section 4.2.
If patients present signs or symptoms suggestive of infection, a prompt investigation should be carried out.
This medicinal product contains 15.96 mg sorbitol in each capsule.
The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account. The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly.
This medicinal product contains 7.5 mg alcohol (ethanol) in each capsule.
The amount in each capsule of this medicine is equivalent to less than 1 ml beer or 1 ml wine.
The small amount of alcohol in this medicinal product will not have any noticeable effects.
This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 'sodium-free'.
\*\*Special precautions for use\*\*
Special care should be taken when prescribing for patients with:
- a history of ischaemic heart disease (see section 4.8).
- poor performance status
Vinorelbine medac should not be given concomitantly with radiotherapy if the treatment field includes the liver.
This medicinal product is specifically contraindicated with yellow fever vaccine and its concomitant use with other live attenuated vaccines is not recommended (see section 4.3).
Caution must be exercised when combining Vinorelbine medac and strong inhibitors or inducers of CYP3A4 (see section 4.5), and its combination with phenytoin (like all cytotoxics) and with itraconazole (like all vinca alkaloids) is not recommended.
Vinorelbine capsules have been studied in patients with liver impairment at the following doses:
- 60 mg/m2 in 7 patients with mild hepatic disorder (bilirubin < 1.5 x ULN, and ALT and/or AST from 1.5 to 2.5 x ULN)
- 50 mg/m2 in 6 patients with moderate hepatic disorder (bilirubin between 1.5 and 3 x ULN, independent of ALT and AST level)
Total clearance of vinorelbine was neither modified between mild and moderate liver impairment nor was it altered in hepatically impaired patients when compared with clearance in patients with normal liver function.
Vinorelbine medac was not studied in patients with severe hepatic impairment therefore its use is contra-indicated in these patients (see sections 4.2, 4.3, 5.2).
As there is a low level of renal excretion there is no pharmacokinetic rationale for reducing the dose of Vinorelbine medac in patients with impaired kidney function (see sections 4.2 and 5.2).4.5 Interaction with other medicinal products and other forms of interaction
\*Concomitant use contraindicated\*
\*\*Yellow fever vaccine\*\*: as with all cytotoxics, risk of fatal generalised vaccine disease (see section 4.3).
\*Concomitant use not recommended\*
\*\*Live attenuated vaccines\*\* (for yellow fever vaccine, see concomitant use contraindicated): as with all cytotoxics, risk of generalised vaccine disease, possibly fatal. This risk is increased in patients already immunodepressed by their underlying disease. It is recommended to use an inactivated vaccine where one exists (e.g. poliomyelitis, see section 4.4).
\*\*Phenytoin\*\*: as with all cytotoxics, risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption by cytotoxic medicinal products or loss of efficacy of the cytotoxic medicinal product due to increased hepatic metabolism by phenytoin.
\*\*Itraconazole\*\*: as with all vinca-alkaloids, increased neurotoxicity of vinca alkaloids due to the decrease of their hepatic metabolism.
\*Concomitant use to take into consideration\*
\*\*Cisplatin\*\*: There is no mutual pharmacokinetic interaction when combining vinorelbine with cisplatin over several cycles of treatment. However, the incidence of granulocytopenia associated with vinorelbine in combination with cisplatin was higher than the one associated with vinorelbine single agent.
\*\*Mitomycin C\*\*: risk of bronchospasm and dyspnoea are increased, in rare cases an interstitial pneumonitis was observed.
\*\*Ciclosporin, tacrolimus\*\*: excessive immunodepression with risk of lymphoproliferation.
As vinca alkaloids are known as substrates for P-glycoprotein, and in the absence of specific study, caution should be exercised when combining Vinorelbine medac with strong modulators of this membrane transporter.
The combination of Vinorelbine medac with other medicinal products with known bone marrow toxicity is likely to exacerbate the myelosuppressive adverse effects.
No clinically significant pharmacokinetic interaction was observed when combining Vinorelbine medac with several other chemotherapeutic agents (paclitaxel, docetaxel, capecitabine and oral cyclophosphamide).
As CYP 3A4 is mainly involved in the metabolism of vinorelbine, combination with strong inhibitors of this isoenzyme (e.g. azole antifungals such as ketoconazole, itraconazole) could increase blood concentrations of vinorelbine, and combination with strong inducers of this isoenzyme (e.g. rifampicin, phenytoin) could decrease blood concentrations of vinorelbine.
Anti-emetic medicinal products such as 5HT3 antagonists (e.g. ondansetron, granisetron) do not modify the pharmacokinetics of Vinorelbine medac (see section 4.4).
\*\*Anticoagulant treatment\*\*: As with all cytotoxics, the frequency of INR (International Normalised Ratio) monitoring should be increased due to the potential interaction with oral anticoagulants and increased variability of coagulation in patients with cancer.
Food does not modify the pharmacokinetics of vinorelbine.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Vinorelbine medac is suspected to cause serious birth effects when administered during pregnancy (see section 5.3).
Vinorelbine medac is contra-indicated in pregnancy (see section 4.3).
In case of a vital indication for treatment with Vinorelbine medac during pregnancy a medical consultation concerning the risk of harmful effects for the child should be conducted. If pregnancy occurs during treatment genetic counselling should be offered.
\*\*Women of child-bearing potential\*\*
Women of child-bearing potential must use effective contraception during treatment and for at least 190 days after treatment.
\*\*Lactation\*\*
It is unknown whether vinorelbine is excreted in human breast milk.
The excretion of vinorelbine in milk has not been studied in animal studies.
A risk to the breastfed infant cannot be excluded; therefore, breastfeeding must be discontinued before starting treatment with Vinorelbine medac (see section 4.3).
\*\*Fertility\*\*
Men being treated with Vinorelbine medac are advised not to father a child during and for at least 100 days after treatment (see section 4.3). Prior to treatment advice should be sought on conserving sperm due to the chance of irreversible infertility as a consequence of treatment with vinorelbine.4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed but on the basis of the pharmacodynamic profile vinorelbine does not affect the ability to drive and use machines. However, caution is necessary in patients treated with vinorelbine considering some of the adverse effects of the drug (see section 4.8).4.8 Undesirable effects
The overall reported frequency of undesirable effects was determined from clinical studies in 316 patients (132 patients with non-small cell lung cancer and 184 patients with breast cancer) who received the recommended regimen of vinorelbine (first three administrations at 60 mg/m2/week followed by 80 mg/m2/week).
Adverse reactions reported are listed below, by system organ class and by frequency.
Additional adverse reactions pooled from post-marketing experience and clinical trials have been added according to the MedDRA classification with the frequency Not known.
The reactions were described using the NCI common toxicity criteria
| | |
| --- | --- |
| Very common | ≥1/10 |
| Common | ≥1/100 to <1/10 |
| Uncommon | ≥1/1,000 to <1/100 |
| Rare | ≥1/10,000 to <1/1,000 |
| Very rare | <1/10,000 |
| Not known | Cannot be estimated from the available data |
\*\*Undesirable effects reported with Vinorelbine medac\*\*
\*Pre-marketing experience\*
The most commonly reported adverse drug reactions are bone marrow depression with neutropenia, anaemia and thrombocytopenia, gastrointestinal toxicity with nausea, vomiting, diarrhoea, stomatitis and constipation. Fatigue and fever were also reported very commonly.
\*Post-marketing experience\*
Vinorelbine medac is used as single agent or in combination with other chemotherapeutic or targeted therapy agents such as cisplatin or capecitabine.
The most commonly involved system organ classes during post-marketing experience are: 'Blood and lymphatic system disorders', 'Gastrointestinal disorders', and 'General disorders and administration site conditions'. This information is consistent with the pre-marketing experience.
| | |
| --- | --- |
| \*Infections and infestations\* | |
| Very common: | Bacterial, viral or fungal infections without neutropenia at different sites G1-4: 12.7 %; G3-4: 4.4 % |
| Common: | Bacterial, viral or fungal infections resulting from bone marrow depression and/or immune system compromise (neutropenic infections) are usually reversible with appropriate treatment Neutropenic infection G3-4: 3.5 % |
| Not known: | Neutropenic sepsis Complicated septicaemia and sometimes fatal Severe sepsis sometimes with other organ failure Septicaemia |
| \*Blood and lymphatic system disorders\* | |
| Very common: | Bone marrow depression resulting mainly in neutropenia G1-4: 71.5 %; G3: 21.8 %; G 4: 25.9 %, is reversible and is the dose-limiting toxicity Leucopenia G1-4: 70.6 %; G3: 24.7 %; G4: 6 % Anaemia G1-4: 67.4 %; G3-4: 3.8 % Thrombocytopenia G1-2: 10.8 % |
| Common: | G4 neutropenia associated with fever over 38 °C including febrile neutropenia: 2.8 % |
| Not known: | Thrombocytopenia G3-4 Pancytopenia |
| \*Endocrine disorders\* | |
| Not known: | Inappropriate antidiuretic hormone secretion (SIADH) |
| \*Metabolism and nutrition disorders\* | |
| Very common: | Anorexia G1-2: 34.5 %; G3-4: 4.1 % |
| Not known: | Severe hyponatraemia |
| \*Psychiatric disorders\* | |
| Common: | Insomnia G1-2: 2.8 % |
| \*Nervous system disorders\* | |
| Very common: | Neurosensory disorders G1-2: 11.1 % were generally limited to loss of tendon reflexes and infrequently severe |
| Common: | Neuromotor disorders G1-4: 9.2 %; G3-4: 1.3 % Headache: G1-4: 4.1 %, G3-4: 0.6 % Dizziness: G1-4: 6 %; G3-4: 0.6 % Taste disorders: G1-2: 3.8 % |
| Uncommon: | Ataxia G3: 0.3 % |
| Not known: | Posterior reversible encephalopathy syndrome |
| \*Eye disorders\* | |
| Common: | Visual impairment G1-2: 1.3 % |
| \*Cardiac disorders\* | |
| Uncommon: | Heart failure, cardiac dysrhythmia |
| Not known: | Myocardial infarction in patients with cardiac medical history or cardiac risk factors |
| \*Vascular disorders\* | |
| Common: | Arterial hypertension G1-4: 2.5 %; G3-4: 0.3 % Arterial hypotension G1-4: 2.2 %; G3-4: 0.6 % |
| \*Respiratory, thoracic and mediastinal disorders\* | |
| Common: | Dyspnoea G1-4: 2.8 %; G3-4: 0.3 % Cough: G1-2: 2.8 % |
| Not known: | Pulmonary embolism |
| \*Gastrointestinal disorders\* | |
| Very common: | Nausea G1-4: 74.7 %; G3-4: 7.3 % Vomiting G1-4: 54.7 %; G 3-4: 6.3 %; supportive treatment (such as oral setrons) may reduce the occurrence of nausea and vomiting Diarrhoea G1-4: 49.7 %; G3-4: 5.7 % Stomatitis G1-4:10.4 %; G3-4: 0.9 % Abdominal pain: G1-4: 14.2 % Constipation G1-4: 19 %; G3-4: 0.9 %. Prescription of laxatives may be appropriate in patients with prior history of constipation and/or who received concomitant treatment with morphine or morphine-mimetics. Gastric disorders: G1-4: 11.7 % |
| Common: | Oesophagitis G1-3: 3.8 %; G3: 0.3 % Dysphagia: G1-2: 2.3 % |
| Uncommon: | Paralytic ileus G3-4: 0.9 % fatal in exceptional cases], treatment may be resumed after recovery of normal bowel mobility |
| Not known: | Gastrointestinal bleeding |
| \*Hepatobiliary disorders\* | |
| Common: | Hepatic disorders: G1-2: 1.3 % |
| Not known: | Transient elevations of liver function tests |
| \*Skin and subcutaneous tissue disorders\* | |
| Very common: | Alopecia, usually mild in nature, G1-2: 29.4 % |
| Common: | Skin reactions G1-2: 5.7 % |
| \*Musculoskeletal and connective tissue disorders\* | |
| Common: | Arthralgia including jaw pain Myalgia G1-4: 7 %, G3-4: 0.3 % |
| \*Renal and urinary disorders\* | |
| Common: | Dysuria G1-2: 1.6 % Other genitourinary symptom G1-2: 1.9 % |
| \*General disorders and administration site conditions\* | |
| Very common: | Fatigue/malaise G1-4: 36.7 %; G3-4: 8.5 % Fever G1-4: 13.0 %, G3-4: 12.1 % |
| Common: | Pain including pain at the tumour site G1-4: 3.8%, G3-4: 0.6% Chills G1-2: 3.8 % |
| \*Investigations\* | |
| Very common: | Weight loss G1-4: 25 %, G3-4: 0.3 % |
| Common: | Weight gain G1-2: 1.3 % |
For the intravenous formulation of vinorelbine, the following additional adverse drug reactions were reported: systemic allergic reactions, severe paraesthesias, weakness of lower extremities, heart rhythm disorders, flushing, peripheral coldness, collapse, angina pectoris, bronchospasm, interstitial pneumopathy, pancreatitis, palmar-plantar erythrodysaesthesia syndrome, acute respiratory distress syndrome.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
\*\*Symptoms\*\*
Overdose with Vinorelbine medac could produce bone marrow hypoplasia sometimes associated with infection, fever, paralytic ileus and hepatic disorders.
\*\*Emergency procedure\*\*
• General supportive measures together with blood transfusion, growth factors and broad spectrum antibiotic therapy should be instituted as deemed necessary by the physician. A close monitoring of hepatic function is recommended.
• Antidote
There is no known antidote for overdose of Vinorelbine medac\*\*.\*\*
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: vinca alkaloids and analogues, ATC code: L01C A04
Vinorelbine medac is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerisation and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralisation is less than that produced by vincristine.
Vinorelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.Safety and efficacy of vinorelbine in paediatric patients have not been established. Clinical data from two single arm phase II studies using intravenous vinorelbine in 33 and 46 paediatric patients with recurrent solid tumours, including rhabdomyosarcoma, other soft tissue sarcoma, Ewing sarcoma, liposarcoma, synovial sarcoma, fibrosarcoma, central nervous system cancer, osteosarcoma, or neuroblastoma, at doses of 30 to 33.75 mg/m2 D1 and D8 every 3 weeks or once weekly for 6 weeks every 8 weeks, showed no meaningful clinical activity. The toxicity profile was similar to that reported in adult patients (see section 4.2).5.2 Pharmacokinetic properties
Pharmacokinetic parameters of vinorelbine were evaluated in blood.
\*\*Absorption\*\*
After oral administration, vinorelbine is rapidly absorbed and the Tmax is reached between 1.5 to 3 h with a blood concentration peak (Cmax) of approximately 130 ng/ml after a dose of 80 mg/m2.
Absolute bioavailability is approximately 40% and a simultaneous intake of food does not alter the exposure to vinorelbine.
Oral vinorelbine at 60 and 80 mg/m2 leads to blood exposure comparable to that achieved with intravenous vinorelbine at 25 and 30 mg/m2, respectively.
The blood exposure to vinorelbine increases proportionally with doses up to 100 mg/m2.
Interindividual variability of the exposure is similar after administration by intravenous and oral routes.
\*\*Distribution\*\*
The steady-state volume of distribution is large, on average 21.2 l.kg-1 (range: 7.5-39.7 l.kg-1), which indicates extensive tissue distribution.
Binding to plasma proteins is weak (13.5%), vinorelbine binds strongly to blood cells and especially to platelets (78%).
There is a significant uptake of vinorelbine in lungs, as assessed by pulmonary surgical biopsies which showed concentrations up to a 300-fold higher than in serum. Vinorelbine is not found in the central nervous system.
\*\*Biotransformation\*\*
All metabolites of vinorelbine are formed by the CYP3A4 isoform of cytochrome P450, except 4-O-deacetylvinorelbine likely to be formed by carboxylesterases. 4-O-deacetylvinorelbine is the only active metabolite and the main one observed in blood.
Neither sulfate nor glucuronide conjugates are found.
\*\*Elimination\*\*
The mean terminal half-life of vinorelbine is around 40 hours. Blood clearance is high, approaching hepatic blood flow, and is 0.72 l/h/kg (range: 0.32-1.26 l/h/kg).
Renal elimination is low (< 5% of the dose administered) and consists mostly of parent compound. Biliary excretion is the predominant elimination route of both unchanged vinorelbine, which is the mainly recovered compound, and its metabolites.
\*\*Special patient groups\*\*
\*Renal and liver impairment\*
The effects of renal dysfunction on the pharmacokinetics of vinorelbine have not been studied. However, dose reduction in case of reduced renal function is not indicated with vinorelbine due to the low level of renal elimination.
Pharmacokinetics of orally administered vinorelbine were not modified after administration of 60 mg/m2 in 7 patients with mild liver impairment (bilirubin < 1.5 x ULN, and ALAT and/or ASAT from 1.5 to 2.5 x ULN) and of 50 mg/m2 in 6 patients with moderate liver impairment (bilirubin from 1.5 to 3 x ULN, whatever the levels of ALAT and ASAT). Total clearance of vinorelbine was neither modified between mild and moderate impairment nor was it altered in hepatically impaired patients when compared with clearance in patients with normal liver function. No data is available for patients with severe liver impairment, therefore vinorelbine is contraindicated in these patients (see sections 4.2, 4.3 and 4.4).
\*Elderly patients\*
A study with oral vinorelbine in elderly patients (≥ 70 years) with NSCLC demonstrated that pharmacokinetics of vinorelbine were not influenced by age. However, since elderly patients are frail, caution should be exercised when increasing the dose of Vinorelbine medac soft capsules (see section 4.2).
\*\*Pharmacokinetic/pharmacodynamic relationships\*\*
A strong relationship has been demonstrated between blood exposure and depletion of leucocytes or PMNs.5.3 Preclinical safety data
Pre-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity.
Vinorelbine induced chromosome damages but was not mutagenic in Ames test.
It is assumed that vinorelbine can cause mutagenic effects (induction of aneuploidy and polyploidy) in man.
In animal reproductive studies, vinorelbine was embryo-foeto-lethal and teratogenic.
No haemodynamic effects were found in dogs receiving vinorelbine at maximum tolerated dose; only some minor, non-significant disturbances of repolarisation were found as with other vinca alkaloids tested.
No effect on the cardiovascular system was observed in primates receiving repeated doses of vinorelbine over 39 weeks.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
\*\*Capsule filling\*\*
anhydrous ethanol
purified water
glycerol
macrogol 400
\*\*Capsule cover\*\*
gelatin
glycerol
partially dehydrated sorbitol liquid
titanium dioxide (E171)
purified water
Vinorelbine medac 30 mg Soft Capsules: iron red oxide (E172)
\*\*Other ingredients\*\*
printing ink (non-volatile component shellac glaze, black iron oxide (E172), propylene glycol)
medium chain triglycerides6.2 Incompatibilities
Not applicable.6.3 Shelf life
36 months6.4 Special precautions for storage
Store in a refrigerator (2 °C – 8 °C) in the original package in order to protect from light.6.5 Nature and contents of container
PVC / PVDC / aluminum blister pack.
The soft capsules are packed in a child-resistant blister pack.
\*\*Pack sizes\*\*
| | |
| --- | --- |
| Vinorelbine medac 30 mg Soft Capsules: | Pack of 1 blister with 1 soft capsule. Pack of 4 blisters with 1 soft capsule each. |6.6 Special precautions for disposal and other handling
\*\*Instructions for use/handling\*\*
To open the packaging:
1. Cut the blister along the black dotted line
2. Peel the soft plastic foil off
3. Push the capsule through the aluminium foil
Any unused medicinal product or waste material should be disposed of in accordance with local requirements\*\*.\*\*
- Instruction Content
- ## Composition
Each soft capsule contains vinorelbine tartrate equivalent to 30 mg vinorelbine
\*\*Excipient(s) with known effect\*\*
Each soft capsule containing 30 mg vinorelbine contains 15.96 mg sorbitol.
Each soft capsule containing 30 mg vinorelbine contains 7.5 mg ethanol.
For the full list of excipients, see section 6.1
## Pharmaceutical Form
Soft capsules
An oblong-shaped pink soft with a size of 15.0 mm x 6.0mm capsule with black “30” printed on the surface.
## Clinical Particulars
4.1 Therapeutic indications
As a single agent or in combination for:
• The first line treatment of stage 3 or 4 non small cell lung cancer.
• The treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.4.2 Posology and method of administration
\*\*In adult patients\*\*
\*\*\*\*As a single agent,\*\*\*\* \*\*the recommended regimen is:\*\*
\*First three administrations\*
60 mg/m2 of body surface area, \*\*administered once weekly.\*\*
\*Subsequent administrations\*
Beyond the third administration, it is recommended to increase the dose of Vinorelbine medac to 80 mg/m2 once weekly except in those patients for whom the neutrophil count dropped once below 500/mm3 or more than once between 500 and 1000/mm3 during the first three administrations at 60 mg/m2.
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Neutrophil count during the first 3 administrations of 60 mg/m2/week\*\* | \*\*Neutrophils\*\* \*\*> 1000\*\* | \*\*Neutrophils\*\* \*\*≥ 500 and < 1000\*\* \*\*(1 episode)\*\* | \*\*Neutrophils\*\* \*\*≥ 500 and < 1000\*\* \*\*(2 episodes)\*\* | \*\*Neutrophils\*\* \*\*< 500\*\* |
| \*\*Recommended dose starting with the 4th administration\*\* | \*\*80\*\* | \*\*80\*\* | \*\*60\*\* | \*\*60\*\* |
\*Dose modification\*
For any administration planned to be given at 80 mg/m2, if the neutrophil count is below 500/mm3 or more than once between 500 and 1000/mm3, the administration should be delayed until recovery and the dose reduced from 80 to 60 mg/m2 per week during the 3 following administrations.
If the neutrophil count is below 1500/mm3 and/or the platelet count below 100000/mm3, then the treatment should be delayed until recovery.
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Neutrophil count beyond the 4th administration of 80 mg/m2/week\*\* | \*\*Neutrophils\*\* \*\*> 1000\*\* | \*\*Neutrophils\*\* \*\*≥ 500 and < 1000\*\* \*\*(1 episode)\*\* | \*\*Neutrophils\*\* \*\*≥ 500 and < 1000\*\* \*\*(2 episodes)\*\* | \*\*Neutrophils\*\* \*\*< 500\*\* |
| \*\*Recommended dose starting with the next administration\*\* | \*\*80\*\* | | \*\*60\*\* | |
It is possible to re-escalate the dose from 60 to 80 mg/m2 per week if the neutrophil count did not drop below 500/mm3 or more than once between 500 and 1000/mm3 during 3 administrations given at 60 mg/m2 according to the rules previously defined for the first 3 administrations.
\*\*For combination regimens, the dose and schedule will be adapted to the treatment protocol.\*\*
Based on clinical studies, the oral dose of 80 mg/m2 was demonstrated to correspond to 30 mg/m2 of the iv form and 60 mg/m2 to 25 mg/m2.
This has been the base for combination regimens alternating iv and oral forms to improve patients' convenience.
Capsules of different strengths (20, 30, 80 mg) are available in order to choose the adequate combination for the right dosage.
The following table gives the dose required for appropriate ranges of body surface area (BSA).
| | | |
| --- | --- | --- |
| | 60 mg/m2 | 80 mg/m2 |
| BSA (m2) | Dose (mg) | Dose (mg) |
| 0.95 to 1.04 | 60 | 80 |
| 1.05 to 1.14 | 70 | 90 |
| 1.15 to 1.24 | 70 | 100 |
| 1.25 to 1.34 | 80 | 100 |
| 1.35 to 1.44 | 80 | 110 |
| 1.45 to 1.54 | 90 | 120 |
| 1.55 to 1.64 | 100 | 130 |
| 1.65 to 1.74 | 100 | 140 |
| 1.75 to 1.84 | 110 | 140 |
| 1.85 to 1.94 | 110 | 150 |
| ≥ 1.95 | 120 | 160 |
Even for patients with BSA ≥ 2 m2 the total dose should never exceed 120 mg per week at 60 mg/m2 and 160 mg per week at 80 mg/m2.
\*\*Administration\*\*
Vinorelbine medac must be given strictly by the oral route.
The Vinorelbine medac capsules must be swallowed whole with water without chewing, sucking or dissolving the capsule.
It is recommended to administer the capsule with some food.
Specific instructions must be followed for the administration of vinorelbine (see section 6.6).
\*Administration in the elderly\*
Clinical experience has not detected any significant differences among elderly patients with regard to the response rate, although greater sensitivity in some of these patients cannot be excluded. Age does not modify the pharmacokinetics of vinorelbine (see section 5.2).
\*Administration in children\*
Safety and efficacy in children have not been established and administration is therefore not recommended.
\*Administration in patients with liver insufficiency\*
Vinorelbine can be administered at the standard dose of 60 mg/m2/week in patients with mild liver impairment (bilirubin < 1.5 x ULN, and ALAT and/or ASAT from 1.5 to 2.5 x ULN).
In patients with moderate liver impairment (bilirubin from 1.5 to 3 x ULN, whatever the levels of ALAT and ASAT), Vinorelbine medac should be administered at a dose of 50 mg/m2/week. The administration of vinorelbine to patients with severe hepatic impairment is contraindicated (see sections 4.3, 4.4 and 5.2).
\*Administration in patients with renal insufficiency\*
Given the minor renal excretion, there is no pharmacokinetic justification for reducing the dose of Vinorelbine medac in patients with serious renal insufficiency (see sections 4.4 and 5.2).4.3 Contraindications
- Known hypersensitivity to vinorelbine or other vinca alkaloids or to any of the constituents
- Disease significantly affecting absorption
- Previous significant surgical resection of stomach or small bowel
- Neutrophil count < 1500/mm3 or severe infection current or recent (within 2 weeks)
- Platelet count < 100 000/mm3
- Severe hepatic insufficiency
- Pregnancy (see section 4.6)
- Lactation (see section 4.6)
- Patients requiring long-term oxygen therapy
- In combination with yellow fever vaccine (see section 4.5)4.4 Special warnings and precautions for use
\*\*Special warnings\*\*
Vinorelbine medac should be prescribed by a physician who is experienced in the use of chemotherapy with facilities for monitoring cytotoxic drugs.
If the patient chews or sucks the capsule by error, the liquid is an irritant. Proceed to mouth rinses with water or preferably a normal saline solution.
In the event of the capsule being cut or damaged, the liquid content is an irritant, and so may cause damage if in contact with skin, mucosa or eyes. Damaged capsules should not be swallowed and should be returned to the pharmacy or to the doctor in order to be properly destroyed. If any contact occurs, immediate thorough washing with water or preferably with normal saline solution should be undertaken.
In the case of vomiting within a few hours after drug intake, do not re-administer. Supportive treatment such as metoclopramide or 5HT3 antagonists (e.g. ondansetron, granisetron) may reduce the occurrence of this (see section 4.5).
Vinorelbine medac is associated with a higher incidence of nausea/vomiting than the intravenous formulation. Primary prophylaxis with antiemetics and administration of the capsules with some food is recommended as this has also been shown to reduce the incidence of nausea and vomiting (see section 4.2).
Patients receiving concomitant morphine or opioid analgesics: laxatives and careful monitoring of bowel mobility are recommended. Prescription of laxatives may be appropriate in patients with prior history of constipation.
Close haematological monitoring must be undertaken during treatment (determination of haemoglobin level and the leucocyte, neutrophil and platelet counts on the day of each new administration).
Dosing should be determined by haematological status:
- If the neutrophil count is below 1500/mm3 and/or the platelet count is below 100 000/mm3, then the treatment should be delayed until recovery.
- For dose escalation from 60 to 80 mg/m2 per week after the third administration, please see section 4.2.
- For the administrations given at 80 mg/m2, if the neutrophil count is below 500/mm3 or more than once between 500 and 1000/mm3, then the treatment should be delayed until recovery. The administration should not only be delayed but also reduced to 60 mg/m2 per week. It is possible to re-escalate the dose from 60 to 80 mg/m2 per week, please see section 4.2.
During clinical trials where treatments were initiated at 80 mg/m2, a few patients developed excessive neutropenic complications, including those with a poor performance status. Therefore, it is recommended that the starting dose should be 60 mg/m2 escalating to 80 mg/m2 if the dose is tolerated as described in section 4.2.
If patients present signs or symptoms suggestive of infection, a prompt investigation should be carried out.
This medicinal product contains 15.96 mg sorbitol in each capsule.
The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account. The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly.
This medicinal product contains 7.5 mg alcohol (ethanol) in each capsule.
The amount in each capsule of this medicine is equivalent to less than 1 ml beer or 1 ml wine.
The small amount of alcohol in this medicinal product will not have any noticeable effects.
This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 'sodium-free'.
\*\*Special precautions for use\*\*
Special care should be taken when prescribing for patients with:
- a history of ischaemic heart disease (see section 4.8).
- poor performance status
Vinorelbine medac should not be given concomitantly with radiotherapy if the treatment field includes the liver.
This medicinal product is specifically contraindicated with yellow fever vaccine and its concomitant use with other live attenuated vaccines is not recommended (see section 4.3).
Caution must be exercised when combining Vinorelbine medac and strong inhibitors or inducers of CYP3A4 (see section 4.5), and its combination with phenytoin (like all cytotoxics) and with itraconazole (like all vinca alkaloids) is not recommended.
Vinorelbine capsules have been studied in patients with liver impairment at the following doses:
- 60 mg/m2 in 7 patients with mild hepatic disorder (bilirubin < 1.5 x ULN, and ALT and/or AST from 1.5 to 2.5 x ULN)
- 50 mg/m2 in 6 patients with moderate hepatic disorder (bilirubin between 1.5 and 3 x ULN, independent of ALT and AST level)
Total clearance of vinorelbine was neither modified between mild and moderate liver impairment nor was it altered in hepatically impaired patients when compared with clearance in patients with normal liver function.
Vinorelbine medac was not studied in patients with severe hepatic impairment therefore its use is contra-indicated in these patients (see sections 4.2, 4.3, 5.2).
As there is a low level of renal excretion there is no pharmacokinetic rationale for reducing the dose of Vinorelbine medac in patients with impaired kidney function (see sections 4.2 and 5.2).4.5 Interaction with other medicinal products and other forms of interaction
\*Concomitant use contraindicated\*
\*\*Yellow fever vaccine\*\*: as with all cytotoxics, risk of fatal generalised vaccine disease (see section 4.3).
\*Concomitant use not recommended\*
\*\*Live attenuated vaccines\*\* (for yellow fever vaccine, see concomitant use contraindicated): as with all cytotoxics, risk of generalised vaccine disease, possibly fatal. This risk is increased in patients already immunodepressed by their underlying disease. It is recommended to use an inactivated vaccine where one exists (e.g. poliomyelitis, see section 4.4).
\*\*Phenytoin\*\*: as with all cytotoxics, risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption by cytotoxic medicinal products or loss of efficacy of the cytotoxic medicinal product due to increased hepatic metabolism by phenytoin.
\*\*Itraconazole\*\*: as with all vinca-alkaloids, increased neurotoxicity of vinca alkaloids due to the decrease of their hepatic metabolism.
\*Concomitant use to take into consideration\*
\*\*Cisplatin\*\*: There is no mutual pharmacokinetic interaction when combining vinorelbine with cisplatin over several cycles of treatment. However, the incidence of granulocytopenia associated with vinorelbine in combination with cisplatin was higher than the one associated with vinorelbine single agent.
\*\*Mitomycin C\*\*: risk of bronchospasm and dyspnoea are increased, in rare cases an interstitial pneumonitis was observed.
\*\*Ciclosporin, tacrolimus\*\*: excessive immunodepression with risk of lymphoproliferation.
As vinca alkaloids are known as substrates for P-glycoprotein, and in the absence of specific study, caution should be exercised when combining Vinorelbine medac with strong modulators of this membrane transporter.
The combination of Vinorelbine medac with other medicinal products with known bone marrow toxicity is likely to exacerbate the myelosuppressive adverse effects.
No clinically significant pharmacokinetic interaction was observed when combining Vinorelbine medac with several other chemotherapeutic agents (paclitaxel, docetaxel, capecitabine and oral cyclophosphamide).
As CYP 3A4 is mainly involved in the metabolism of vinorelbine, combination with strong inhibitors of this isoenzyme (e.g. azole antifungals such as ketoconazole, itraconazole) could increase blood concentrations of vinorelbine, and combination with strong inducers of this isoenzyme (e.g. rifampicin, phenytoin) could decrease blood concentrations of vinorelbine.
Anti-emetic medicinal products such as 5HT3 antagonists (e.g. ondansetron, granisetron) do not modify the pharmacokinetics of Vinorelbine medac (see section 4.4).
\*\*Anticoagulant treatment\*\*: As with all cytotoxics, the frequency of INR (International Normalised Ratio) monitoring should be increased due to the potential interaction with oral anticoagulants and increased variability of coagulation in patients with cancer.
Food does not modify the pharmacokinetics of vinorelbine.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Vinorelbine medac is suspected to cause serious birth effects when administered during pregnancy (see section 5.3).
Vinorelbine medac is contra-indicated in pregnancy (see section 4.3).
In case of a vital indication for treatment with Vinorelbine medac during pregnancy a medical consultation concerning the risk of harmful effects for the child should be conducted. If pregnancy occurs during treatment genetic counselling should be offered.
\*\*Women of child-bearing potential\*\*
Women of child-bearing potential must use effective contraception during treatment and for at least 190 days after treatment.
\*\*Lactation\*\*
It is unknown whether vinorelbine is excreted in human breast milk.
The excretion of vinorelbine in milk has not been studied in animal studies.
A risk to the breastfed infant cannot be excluded; therefore, breastfeeding must be discontinued before starting treatment with Vinorelbine medac (see section 4.3).
\*\*Fertility\*\*
Men being treated with Vinorelbine medac are advised not to father a child during and for at least 100 days after treatment (see section 4.3). Prior to treatment advice should be sought on conserving sperm due to the chance of irreversible infertility as a consequence of treatment with vinorelbine.4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed but on the basis of the pharmacodynamic profile vinorelbine does not affect the ability to drive and use machines. However, caution is necessary in patients treated with vinorelbine considering some of the adverse effects of the drug (see section 4.8).4.8 Undesirable effects
The overall reported frequency of undesirable effects was determined from clinical studies in 316 patients (132 patients with non-small cell lung cancer and 184 patients with breast cancer) who received the recommended regimen of vinorelbine (first three administrations at 60 mg/m2/week followed by 80 mg/m2/week).
Adverse reactions reported are listed below, by system organ class and by frequency.
Additional adverse reactions pooled from post-marketing experience and clinical trials have been added according to the MedDRA classification with the frequency Not known.
The reactions were described using the NCI common toxicity criteria
| | |
| --- | --- |
| Very common | ≥1/10 |
| Common | ≥1/100 to <1/10 |
| Uncommon | ≥1/1,000 to <1/100 |
| Rare | ≥1/10,000 to <1/1,000 |
| Very rare | <1/10,000 |
| Not known | Cannot be estimated from the available data |
\*\*Undesirable effects reported with Vinorelbine medac\*\*
\*Pre-marketing experience\*
The most commonly reported adverse drug reactions are bone marrow depression with neutropenia, anaemia and thrombocytopenia, gastrointestinal toxicity with nausea, vomiting, diarrhoea, stomatitis and constipation. Fatigue and fever were also reported very commonly.
\*Post-marketing experience\*
Vinorelbine medac is used as single agent or in combination with other chemotherapeutic or targeted therapy agents such as cisplatin or capecitabine.
The most commonly involved system organ classes during post-marketing experience are: 'Blood and lymphatic system disorders', 'Gastrointestinal disorders', and 'General disorders and administration site conditions'. This information is consistent with the pre-marketing experience.
| | |
| --- | --- |
| \*Infections and infestations\* | |
| Very common: | Bacterial, viral or fungal infections without neutropenia at different sites G1-4: 12.7 %; G3-4: 4.4 % |
| Common: | Bacterial, viral or fungal infections resulting from bone marrow depression and/or immune system compromise (neutropenic infections) are usually reversible with appropriate treatment Neutropenic infection G3-4: 3.5 % |
| Not known: | Neutropenic sepsis Complicated septicaemia and sometimes fatal Severe sepsis sometimes with other organ failure Septicaemia |
| \*Blood and lymphatic system disorders\* | |
| Very common: | Bone marrow depression resulting mainly in neutropenia G1-4: 71.5 %; G3: 21.8 %; G 4: 25.9 %, is reversible and is the dose-limiting toxicity Leucopenia G1-4: 70.6 %; G3: 24.7 %; G4: 6 % Anaemia G1-4: 67.4 %; G3-4: 3.8 % Thrombocytopenia G1-2: 10.8 % |
| Common: | G4 neutropenia associated with fever over 38 °C including febrile neutropenia: 2.8 % |
| Not known: | Thrombocytopenia G3-4 Pancytopenia |
| \*Endocrine disorders\* | |
| Not known: | Inappropriate antidiuretic hormone secretion (SIADH) |
| \*Metabolism and nutrition disorders\* | |
| Very common: | Anorexia G1-2: 34.5 %; G3-4: 4.1 % |
| Not known: | Severe hyponatraemia |
| \*Psychiatric disorders\* | |
| Common: | Insomnia G1-2: 2.8 % |
| \*Nervous system disorders\* | |
| Very common: | Neurosensory disorders G1-2: 11.1 % were generally limited to loss of tendon reflexes and infrequently severe |
| Common: | Neuromotor disorders G1-4: 9.2 %; G3-4: 1.3 % Headache: G1-4: 4.1 %, G3-4: 0.6 % Dizziness: G1-4: 6 %; G3-4: 0.6 % Taste disorders: G1-2: 3.8 % |
| Uncommon: | Ataxia G3: 0.3 % |
| Not known: | Posterior reversible encephalopathy syndrome |
| \*Eye disorders\* | |
| Common: | Visual impairment G1-2: 1.3 % |
| \*Cardiac disorders\* | |
| Uncommon: | Heart failure, cardiac dysrhythmia |
| Not known: | Myocardial infarction in patients with cardiac medical history or cardiac risk factors |
| \*Vascular disorders\* | |
| Common: | Arterial hypertension G1-4: 2.5 %; G3-4: 0.3 % Arterial hypotension G1-4: 2.2 %; G3-4: 0.6 % |
| \*Respiratory, thoracic and mediastinal disorders\* | |
| Common: | Dyspnoea G1-4: 2.8 %; G3-4: 0.3 % Cough: G1-2: 2.8 % |
| Not known: | Pulmonary embolism |
| \*Gastrointestinal disorders\* | |
| Very common: | Nausea G1-4: 74.7 %; G3-4: 7.3 % Vomiting G1-4: 54.7 %; G 3-4: 6.3 %; supportive treatment (such as oral setrons) may reduce the occurrence of nausea and vomiting Diarrhoea G1-4: 49.7 %; G3-4: 5.7 % Stomatitis G1-4:10.4 %; G3-4: 0.9 % Abdominal pain: G1-4: 14.2 % Constipation G1-4: 19 %; G3-4: 0.9 %. Prescription of laxatives may be appropriate in patients with prior history of constipation and/or who received concomitant treatment with morphine or morphine-mimetics. Gastric disorders: G1-4: 11.7 % |
| Common: | Oesophagitis G1-3: 3.8 %; G3: 0.3 % Dysphagia: G1-2: 2.3 % |
| Uncommon: | Paralytic ileus G3-4: 0.9 % fatal in exceptional cases], treatment may be resumed after recovery of normal bowel mobility |
| Not known: | Gastrointestinal bleeding |
| \*Hepatobiliary disorders\* | |
| Common: | Hepatic disorders: G1-2: 1.3 % |
| Not known: | Transient elevations of liver function tests |
| \*Skin and subcutaneous tissue disorders\* | |
| Very common: | Alopecia, usually mild in nature, G1-2: 29.4 % |
| Common: | Skin reactions G1-2: 5.7 % |
| \*Musculoskeletal and connective tissue disorders\* | |
| Common: | Arthralgia including jaw pain Myalgia G1-4: 7 %, G3-4: 0.3 % |
| \*Renal and urinary disorders\* | |
| Common: | Dysuria G1-2: 1.6 % Other genitourinary symptom G1-2: 1.9 % |
| \*General disorders and administration site conditions\* | |
| Very common: | Fatigue/malaise G1-4: 36.7 %; G3-4: 8.5 % Fever G1-4: 13.0 %, G3-4: 12.1 % |
| Common: | Pain including pain at the tumour site G1-4: 3.8%, G3-4: 0.6% Chills G1-2: 3.8 % |
| \*Investigations\* | |
| Very common: | Weight loss G1-4: 25 %, G3-4: 0.3 % |
| Common: | Weight gain G1-2: 1.3 % |
For the intravenous formulation of vinorelbine, the following additional adverse drug reactions were reported: systemic allergic reactions, severe paraesthesias, weakness of lower extremities, heart rhythm disorders, flushing, peripheral coldness, collapse, angina pectoris, bronchospasm, interstitial pneumopathy, pancreatitis, palmar-plantar erythrodysaesthesia syndrome, acute respiratory distress syndrome.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
\*\*Symptoms\*\*
Overdose with Vinorelbine medac could produce bone marrow hypoplasia sometimes associated with infection, fever, paralytic ileus and hepatic disorders.
\*\*Emergency procedure\*\*
• General supportive measures together with blood transfusion, growth factors and broad spectrum antibiotic therapy should be instituted as deemed necessary by the physician. A close monitoring of hepatic function is recommended.
• Antidote
There is no known antidote for overdose of Vinorelbine medac\*\*.\*\*
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: vinca alkaloids and analogues, ATC code: L01C A04
Vinorelbine medac is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerisation and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralisation is less than that produced by vincristine.
Vinorelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.Safety and efficacy of vinorelbine in paediatric patients have not been established. Clinical data from two single arm phase II studies using intravenous vinorelbine in 33 and 46 paediatric patients with recurrent solid tumours, including rhabdomyosarcoma, other soft tissue sarcoma, Ewing sarcoma, liposarcoma, synovial sarcoma, fibrosarcoma, central nervous system cancer, osteosarcoma, or neuroblastoma, at doses of 30 to 33.75 mg/m2 D1 and D8 every 3 weeks or once weekly for 6 weeks every 8 weeks, showed no meaningful clinical activity. The toxicity profile was similar to that reported in adult patients (see section 4.2).5.2 Pharmacokinetic properties
Pharmacokinetic parameters of vinorelbine were evaluated in blood.
\*\*Absorption\*\*
After oral administration, vinorelbine is rapidly absorbed and the Tmax is reached between 1.5 to 3 h with a blood concentration peak (Cmax) of approximately 130 ng/ml after a dose of 80 mg/m2.
Absolute bioavailability is approximately 40% and a simultaneous intake of food does not alter the exposure to vinorelbine.
Oral vinorelbine at 60 and 80 mg/m2 leads to blood exposure comparable to that achieved with intravenous vinorelbine at 25 and 30 mg/m2, respectively.
The blood exposure to vinorelbine increases proportionally with doses up to 100 mg/m2.
Interindividual variability of the exposure is similar after administration by intravenous and oral routes.
\*\*Distribution\*\*
The steady-state volume of distribution is large, on average 21.2 l.kg-1 (range: 7.5-39.7 l.kg-1), which indicates extensive tissue distribution.
Binding to plasma proteins is weak (13.5%), vinorelbine binds strongly to blood cells and especially to platelets (78%).
There is a significant uptake of vinorelbine in lungs, as assessed by pulmonary surgical biopsies which showed concentrations up to a 300-fold higher than in serum. Vinorelbine is not found in the central nervous system.
\*\*Biotransformation\*\*
All metabolites of vinorelbine are formed by the CYP3A4 isoform of cytochrome P450, except 4-O-deacetylvinorelbine likely to be formed by carboxylesterases. 4-O-deacetylvinorelbine is the only active metabolite and the main one observed in blood.
Neither sulfate nor glucuronide conjugates are found.
\*\*Elimination\*\*
The mean terminal half-life of vinorelbine is around 40 hours. Blood clearance is high, approaching hepatic blood flow, and is 0.72 l/h/kg (range: 0.32-1.26 l/h/kg).
Renal elimination is low (< 5% of the dose administered) and consists mostly of parent compound. Biliary excretion is the predominant elimination route of both unchanged vinorelbine, which is the mainly recovered compound, and its metabolites.
\*\*Special patient groups\*\*
\*Renal and liver impairment\*
The effects of renal dysfunction on the pharmacokinetics of vinorelbine have not been studied. However, dose reduction in case of reduced renal function is not indicated with vinorelbine due to the low level of renal elimination.
Pharmacokinetics of orally administered vinorelbine were not modified after administration of 60 mg/m2 in 7 patients with mild liver impairment (bilirubin < 1.5 x ULN, and ALAT and/or ASAT from 1.5 to 2.5 x ULN) and of 50 mg/m2 in 6 patients with moderate liver impairment (bilirubin from 1.5 to 3 x ULN, whatever the levels of ALAT and ASAT). Total clearance of vinorelbine was neither modified between mild and moderate impairment nor was it altered in hepatically impaired patients when compared with clearance in patients with normal liver function. No data is available for patients with severe liver impairment, therefore vinorelbine is contraindicated in these patients (see sections 4.2, 4.3 and 4.4).
\*Elderly patients\*
A study with oral vinorelbine in elderly patients (≥ 70 years) with NSCLC demonstrated that pharmacokinetics of vinorelbine were not influenced by age. However, since elderly patients are frail, caution should be exercised when increasing the dose of Vinorelbine medac soft capsules (see section 4.2).
\*\*Pharmacokinetic/pharmacodynamic relationships\*\*
A strong relationship has been demonstrated between blood exposure and depletion of leucocytes or PMNs.5.3 Preclinical safety data
Pre-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity.
Vinorelbine induced chromosome damages but was not mutagenic in Ames test.
It is assumed that vinorelbine can cause mutagenic effects (induction of aneuploidy and polyploidy) in man.
In animal reproductive studies, vinorelbine was embryo-foeto-lethal and teratogenic.
No haemodynamic effects were found in dogs receiving vinorelbine at maximum tolerated dose; only some minor, non-significant disturbances of repolarisation were found as with other vinca alkaloids tested.
No effect on the cardiovascular system was observed in primates receiving repeated doses of vinorelbine over 39 weeks.
## Pharmaceutical Particulars
6.1 List of excipients
\*\*Capsule filling\*\*
anhydrous ethanol
purified water
glycerol
macrogol 400
\*\*Capsule cover\*\*
gelatin
glycerol
partially dehydrated sorbitol liquid
titanium dioxide (E171)
purified water
Vinorelbine medac 30 mg Soft Capsules: iron red oxide (E172)
\*\*Other ingredients\*\*
printing ink (non-volatile component shellac glaze, black iron oxide (E172), propylene glycol)
medium chain triglycerides6.2 Incompatibilities
Not applicable.6.3 Shelf life
36 months6.4 Special precautions for storage
Store in a refrigerator (2 °C – 8 °C) in the original package in order to protect from light.6.5 Nature and contents of container
PVC / PVDC / aluminum blister pack.
The soft capsules are packed in a child-resistant blister pack.
\*\*Pack sizes\*\*
| | |
| --- | --- |
| Vinorelbine medac 30 mg Soft Capsules: | Pack of 1 blister with 1 soft capsule. Pack of 4 blisters with 1 soft capsule each. |6.6 Special precautions for disposal and other handling
\*\*Instructions for use/handling\*\*
To open the packaging:
1. Cut the blister along the black dotted line
2. Peel the soft plastic foil off
3. Push the capsule through the aluminium foil
Any unused medicinal product or waste material should be disposed of in accordance with local requirements\*\*.\*\*
